Meeting of the Substance Abuse and Mental Health Services Administration, Center for Mental Health Services National Advisory Council, 47153 [2023-15479]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 139 / Friday, July 21, 2023 / Notices
disclosed and claimed in the
prospective licensed patent rights, for
the treatment of inflammatory diseases,
such as hidradenitis suppurativa (HS) in
humans and animals.’’
The subject technology discloses
potent and selective caspase 1 inhibitors
that target the active site of the enzyme.
Several cyanopropanate containing
small molecules were synthesized,
including one based upon the optimized
peptidic scaffold of the prodrug VX–
765. A number of these compounds
were potent inhibitors of caspase 1
(IC50s ≤ 1 nM). Examination of these
small molecules versus a caspase panel
demonstrated an impressive degree of
selectivity for caspase 1 inhibition. The
small molecular probe ML132 (CID–
4462093; NCGC–00183434) is the most
potent caspase 1 inhibitor reported to
date. It also possesses a unique
selectivity pattern relative to other
reported caspase inhibitors. A number
of these compounds were assessed for
their hydrolytic stability and selected
absorption, distribution, metabolism
and elimination (ADME) properties.
Some of the compounds of this
invention could be developed as
effective therapeutics for diseases such
as inflammatory diseases such as
hidradenitis suppurativa (HS), ischemic
disorders, Huntington’s disease,
amyotrophic lateral sclerosis (ALS),
rheumatoid arthritis, osteoarthritis,
inflammatory bowel disease and sepsis.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published Notice, the National
Center for Advancing Translational
Sciences receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
VerDate Sep<11>2014
19:06 Jul 20, 2023
Jkt 259001
Dated: July 16, 2023.
Joni L. Rutter,
Director, Office of the Director, National
Center for Advancing Translational Sciences.
[FR Doc. 2023–15445 Filed 7–20–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Meeting of the Substance Abuse and
Mental Health Services Administration,
Center for Mental Health Services
National Advisory Council
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
Pursuant to Public Law 92–463,
notice is hereby given of the meeting on
August 29, 2023, of the Substance
Abuse and Mental Health Services
Administration (SAMHSA), Center for
Mental Health Services National
Advisory Council (CMHS NAC).
The meeting is open to the public and
will include consideration of the
meeting minutes from the April 25,
2023, SAMHSA, CMHS NAC meeting;
updates from the CMHS Director; a
discussion from SAMHSA’s Assistant
Secretary; a discussion from the
Recovery Office; a discussion on
Olmstead Activity; a discussion on
Transitional Age Youth Policy
Academy; a discussion on Advisory
Committee for Women’s Services/
Gender Based Violence; and a
discussion on Potential Innovation.
The meeting will be held at SAMHSA,
5600 Fishers Lane, 5W11, Rockville, MD
20857. Attendance by the public will be
limited to space available and will be
limited to the open sessions of the
meeting. Interested persons may present
data, information, or views, orally or in
writing, on issues pending before the
Council. Presentations from the public
will be scheduled at the conclusion of
the meeting. Individuals interested in
making public comment must notify the
contact person, Pamela Foote, CMHS
NAC Designated Federal Officer (DFO)
on or before August 18, 2023. Up three
minutes will be allotted for each public
comment as time permits.
Written comments received in
advance of the meeting will be
considered for inclusion in the official
record.
The open meeting session may also be
accessed virtually. Please register online at https://snacregister.samhsa.gov,
to attend either on site or virtually,
submit written or brief oral comments,
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
47153
or request special accommodations for
persons with disabilities. To
communicate with the CMHS NAC DFO
please see the contact information
below.
Meeting information and a roster of
Council members may be obtained by
accessing the SAMHSA Committee
website at https://www.samhsa.gov/
about-us/advisory-councils/cmhsnational-advisory-council or by
contacting the DFO.
Council Name: SAMHSA’s Center for
Mental Health Services National
Advisory Council.
Date/Time/Type: August 29, 2023,
9:00 a.m. to 4:30 p.m. EDT, Open.
Place: SAMHSA, 5600 Fishers Lane,
Rockville, Maryland 20857.
Contact: Pamela Foote, Designated
Federal Officer, CMHS National
Advisory Council, 5600 Fishers Lane,
Rockville, Maryland 20857 (mail),
Telephone: (240) 276–1279, Email:
pamela.foote@samhsa.hhs.gov.
Dated: July 17, 2023.
Carlos Castillo,
Committee Management Officer, SAMHSA.
[FR Doc. 2023–15479 Filed 7–20–23; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Advisory Committee for Women’s
Services (ACWS); Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given of a meeting of
the Substance Abuse and Mental Health
Services Administration’s (SAMHSA)
Advisory Committee for Women’s
Services (ACWS) on August 29, 2023.
The meeting will include discussions
on assessing SAMHSA’s current
strategies, including the mental health
and substance use needs of the women
and girls population. Additionally, the
ACWS will be addressing priorities
regarding Maternal Behavioral Health.
The meeting is open to the public and
will be held at 5600 Fishers Lane,
Rockville, Maryland, 20857. Interested
persons may present data, information,
or views, orally or in writing, on issues
pending before the committee. Written
submissions should be forwarded to the
contact person by August 19, 2023, 3
p.m. Eastern Time. Oral presentations
from the public will be scheduled at the
conclusion of the meeting. Individuals
interested in making oral presentations
must notify the contact person on or
before August 19, 2023, 3 p.m. Eastern
Time. Up to five minutes will be
E:\FR\FM\21JYN1.SGM
21JYN1
]]>Agencies
[Federal Register Volume 88, Number 139 (Friday, July 21, 2023)]
[Notices]
[Page 47153]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-15479]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Meeting of the Substance Abuse and Mental Health Services
Administration, Center for Mental Health Services National Advisory
Council
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
Pursuant to Public Law 92-463, notice is hereby given of the
meeting on August 29, 2023, of the Substance Abuse and Mental Health
Services Administration (SAMHSA), Center for Mental Health Services
National Advisory Council (CMHS NAC).
The meeting is open to the public and will include consideration of
the meeting minutes from the April 25, 2023, SAMHSA, CMHS NAC meeting;
updates from the CMHS Director; a discussion from SAMHSA's Assistant
Secretary; a discussion from the Recovery Office; a discussion on
Olmstead Activity; a discussion on Transitional Age Youth Policy
Academy; a discussion on Advisory Committee for Women's Services/Gender
Based Violence; and a discussion on Potential Innovation.
The meeting will be held at SAMHSA, 5600 Fishers Lane, 5W11,
Rockville, MD 20857. Attendance by the public will be limited to space
available and will be limited to the open sessions of the meeting.
Interested persons may present data, information, or views, orally or
in writing, on issues pending before the Council. Presentations from
the public will be scheduled at the conclusion of the meeting.
Individuals interested in making public comment must notify the contact
person, Pamela Foote, CMHS NAC Designated Federal Officer (DFO) on or
before August 18, 2023. Up three minutes will be allotted for each
public comment as time permits.
Written comments received in advance of the meeting will be
considered for inclusion in the official record.
The open meeting session may also be accessed virtually. Please
register on-line at https://snacregister.samhsa.gov, to attend either
on site or virtually, submit written or brief oral comments, or request
special accommodations for persons with disabilities. To communicate
with the CMHS NAC DFO please see the contact information below.
Meeting information and a roster of Council members may be obtained
by accessing the SAMHSA Committee website at https://www.samhsa.gov/about-us/advisory-councils/cmhs-national-advisory-council or by
contacting the DFO.
Council Name: SAMHSA's Center for Mental Health Services National
Advisory Council.
Date/Time/Type: August 29, 2023, 9:00 a.m. to 4:30 p.m. EDT, Open.
Place: SAMHSA, 5600 Fishers Lane, Rockville, Maryland 20857.
Contact: Pamela Foote, Designated Federal Officer, CMHS National
Advisory Council, 5600 Fishers Lane, Rockville, Maryland 20857 (mail),
Telephone: (240) 276-1279, Email: [email protected].
Dated: July 17, 2023.
Carlos Castillo,
Committee Management Officer, SAMHSA.
[FR Doc. 2023-15479 Filed 7-20-23; 8:45 am]
BILLING CODE 4162-20-P
